Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 485, 298-304
Abstract
No abstract availableKeywords
Funding Information
- King Saud University (RGP-322)
This publication has 15 references indexed in Scilit:
- Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometryClinica Chimica Acta, 2018
- Targeting TRK family proteins in cancerPharmacology & Therapeutics, 2017
- Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidationRSC Advances, 2017
- Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathwaysRSC Advances, 2016
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitorJournal of Medicinal Chemistry, 2016
- Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effectJournal of Chromatography A, 2014
- Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocationLung Cancer, 2014
- Optimization in Drug Discovery2014
- Mechanistic insight into ALK receptor tyrosine kinase in human cancer biologyNature Reviews Cancer, 2013
- The preparation of microsomesNaunyn-Schmiedeberg's Archives of Pharmacology, 1965